Jüstus-liebig-universität Giessen

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Andreas Günther

Werner Seeger

Viktor Magdolen

Thomas Braun

Marcus Krüger

Indrabahadur Singh

Marten Szibor

Philipp Markart

Clemens Ruppert

Guillermo Barreto

Timothy E Weaver

Aditi Mehta

Rajkumar Savai

The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy

The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases.

Chimeric plasminogen activators and their pharmaceutical use

Growing community of inventors

Munich, Georgia

Andreas Günther